Copyright Reports & Markets. All rights reserved.

Global Sickle Cell Disease Drug Market Insights, Forecast to 2025

Buy now

Table of Contents

    1 Study Coverage

    • 1.1 Sickle Cell Disease Drug Product
    • 1.2 Market Segments
    • 1.3 Key Manufacturers Covered
    • 1.4 Market by Type
      • 1.4.1 Global Sickle Cell Disease Drug Market Size Growth Rate by Product
      • 1.4.2 ARQ-092
      • 1.4.3 BIVV-003
      • 1.4.4 CAL-H
      • 1.4.5 CTX-001
      • 1.4.6 DRX-194
      • 1.4.7 Others
    • 1.5 Market by End User
      • 1.5.1 Global Sickle Cell Disease Drug Market Size Growth Rate by End User
      • 1.5.2 Hospital
      • 1.5.3 Clinic
      • 1.5.4 Others
    • 1.6 Study Objectives
    • 1.7 Years Considered

    2 Executive Summary

    • 2.1 Global Sickle Cell Disease Drug Market Size
      • 2.1.1 Global Sickle Cell Disease Drug Revenue 2014-2025
      • 2.1.2 Global Sickle Cell Disease Drug Sales 2014-2025
    • 2.2 Sickle Cell Disease Drug Growth Rate by Regions
      • 2.2.1 Global Sickle Cell Disease Drug Sales by Regions
      • 2.2.2 Global Sickle Cell Disease Drug Revenue by Regions

    3 Breakdown Data by Manufacturers

    • 3.1 Sickle Cell Disease Drug Sales by Manufacturers
      • 3.1.1 Sickle Cell Disease Drug Sales by Manufacturers
      • 3.1.2 Sickle Cell Disease Drug Sales Market Share by Manufacturers
      • 3.1.3 Global Sickle Cell Disease Drug Market Concentration Ratio (CR5 and HHI)
    • 3.2 Sickle Cell Disease Drug Revenue by Manufacturers
      • 3.2.1 Sickle Cell Disease Drug Revenue by Manufacturers (2014-2019)
      • 3.2.2 Sickle Cell Disease Drug Revenue Share by Manufacturers (2014-2019)
    • 3.3 Sickle Cell Disease Drug Price by Manufacturers
    • 3.4 Sickle Cell Disease Drug Manufacturing Base Distribution, Product Types
      • 3.4.1 Sickle Cell Disease Drug Manufacturers Manufacturing Base Distribution, Headquarters
      • 3.4.2 Manufacturers Sickle Cell Disease Drug Product Type
      • 3.4.3 Date of International Manufacturers Enter into Sickle Cell Disease Drug Market
    • 3.5 Manufacturers Mergers & Acquisitions, Expansion Plans

    4 Breakdown Data by Product

    • 4.1 Global Sickle Cell Disease Drug Sales by Product
    • 4.2 Global Sickle Cell Disease Drug Revenue by Product
    • 4.3 Sickle Cell Disease Drug Price by Product

    5 Breakdown Data by End User

    • 5.1 Overview
    • 5.2 Global Sickle Cell Disease Drug Breakdown Data by End User

    6 North America

    • 6.1 North America Sickle Cell Disease Drug by Countries
      • 6.1.1 North America Sickle Cell Disease Drug Sales by Countries
      • 6.1.2 North America Sickle Cell Disease Drug Revenue by Countries
      • 6.1.3 United States
      • 6.1.4 Canada
      • 6.1.5 Mexico
    • 6.2 North America Sickle Cell Disease Drug by Product
    • 6.3 North America Sickle Cell Disease Drug by End User

    7 Europe

    • 7.1 Europe Sickle Cell Disease Drug by Countries
      • 7.1.1 Europe Sickle Cell Disease Drug Sales by Countries
      • 7.1.2 Europe Sickle Cell Disease Drug Revenue by Countries
      • 7.1.3 Germany
      • 7.1.4 France
      • 7.1.5 UK
      • 7.1.6 Italy
      • 7.1.7 Russia
    • 7.2 Europe Sickle Cell Disease Drug by Product
    • 7.3 Europe Sickle Cell Disease Drug by End User

    8 Asia Pacific

    • 8.1 Asia Pacific Sickle Cell Disease Drug by Countries
      • 8.1.1 Asia Pacific Sickle Cell Disease Drug Sales by Countries
      • 8.1.2 Asia Pacific Sickle Cell Disease Drug Revenue by Countries
      • 8.1.3 China
      • 8.1.4 Japan
      • 8.1.5 Korea
      • 8.1.6 India
      • 8.1.7 Australia
      • 8.1.8 Indonesia
      • 8.1.9 Malaysia
      • 8.1.10 Philippines
      • 8.1.11 Thailand
      • 8.1.12 Vietnam
      • 8.1.13 Singapore
    • 8.2 Asia Pacific Sickle Cell Disease Drug by Product
    • 8.3 Asia Pacific Sickle Cell Disease Drug by End User

    9 Central & South America

    • 9.1 Central & South America Sickle Cell Disease Drug by Countries
      • 9.1.1 Central & South America Sickle Cell Disease Drug Sales by Countries
      • 9.1.2 Central & South America Sickle Cell Disease Drug Revenue by Countries
      • 9.1.3 Brazil
    • 9.2 Central & South America Sickle Cell Disease Drug by Product
    • 9.3 Central & South America Sickle Cell Disease Drug by End User

    10 Middle East and Africa

    • 10.1 Middle East and Africa Sickle Cell Disease Drug by Countries
      • 10.1.1 Middle East and Africa Sickle Cell Disease Drug Sales by Countries
      • 10.1.2 Middle East and Africa Sickle Cell Disease Drug Revenue by Countries
      • 10.1.3 GCC Countries
      • 10.1.4 Turkey
      • 10.1.5 Egypt
      • 10.1.6 South Africa
    • 10.2 Middle East and Africa Sickle Cell Disease Drug by Product
    • 10.3 Middle East and Africa Sickle Cell Disease Drug by End User

    11 Company Profiles

    • 11.1 Acceleron Pharma Inc
      • 11.1.1 Acceleron Pharma Inc Company Details
      • 11.1.2 Company Business Overview
      • 11.1.3 Acceleron Pharma Inc Sickle Cell Disease Drug Sales, Revenue and Gross Margin (2014-2019)
      • 11.1.4 Acceleron Pharma Inc Sickle Cell Disease Drug Products Offered
      • 11.1.5 Acceleron Pharma Inc Recent Development
    • 11.2 Addmedica SAS
      • 11.2.1 Addmedica SAS Company Details
      • 11.2.2 Company Business Overview
      • 11.2.3 Addmedica SAS Sickle Cell Disease Drug Sales, Revenue and Gross Margin (2014-2019)
      • 11.2.4 Addmedica SAS Sickle Cell Disease Drug Products Offered
      • 11.2.5 Addmedica SAS Recent Development
    • 11.3 Angiocrine Bioscience Inc
      • 11.3.1 Angiocrine Bioscience Inc Company Details
      • 11.3.2 Company Business Overview
      • 11.3.3 Angiocrine Bioscience Inc Sickle Cell Disease Drug Sales, Revenue and Gross Margin (2014-2019)
      • 11.3.4 Angiocrine Bioscience Inc Sickle Cell Disease Drug Products Offered
      • 11.3.5 Angiocrine Bioscience Inc Recent Development
    • 11.4 Annexin Pharmaceuticals AB
      • 11.4.1 Annexin Pharmaceuticals AB Company Details
      • 11.4.2 Company Business Overview
      • 11.4.3 Annexin Pharmaceuticals AB Sickle Cell Disease Drug Sales, Revenue and Gross Margin (2014-2019)
      • 11.4.4 Annexin Pharmaceuticals AB Sickle Cell Disease Drug Products Offered
      • 11.4.5 Annexin Pharmaceuticals AB Recent Development
    • 11.5 ArQule Inc
      • 11.5.1 ArQule Inc Company Details
      • 11.5.2 Company Business Overview
      • 11.5.3 ArQule Inc Sickle Cell Disease Drug Sales, Revenue and Gross Margin (2014-2019)
      • 11.5.4 ArQule Inc Sickle Cell Disease Drug Products Offered
      • 11.5.5 ArQule Inc Recent Development
    • 11.6 Bio Products Laboratory Ltd
      • 11.6.1 Bio Products Laboratory Ltd Company Details
      • 11.6.2 Company Business Overview
      • 11.6.3 Bio Products Laboratory Ltd Sickle Cell Disease Drug Sales, Revenue and Gross Margin (2014-2019)
      • 11.6.4 Bio Products Laboratory Ltd Sickle Cell Disease Drug Products Offered
      • 11.6.5 Bio Products Laboratory Ltd Recent Development
    • 11.7 Bioverativ Inc
      • 11.7.1 Bioverativ Inc Company Details
      • 11.7.2 Company Business Overview
      • 11.7.3 Bioverativ Inc Sickle Cell Disease Drug Sales, Revenue and Gross Margin (2014-2019)
      • 11.7.4 Bioverativ Inc Sickle Cell Disease Drug Products Offered
      • 11.7.5 Bioverativ Inc Recent Development
    • 11.8 bluebird bio Inc
      • 11.8.1 bluebird bio Inc Company Details
      • 11.8.2 Company Business Overview
      • 11.8.3 bluebird bio Inc Sickle Cell Disease Drug Sales, Revenue and Gross Margin (2014-2019)
      • 11.8.4 bluebird bio Inc Sickle Cell Disease Drug Products Offered
      • 11.8.5 bluebird bio Inc Recent Development
    • 11.9 Bristol-Myers Squibb Co
      • 11.9.1 Bristol-Myers Squibb Co Company Details
      • 11.9.2 Company Business Overview
      • 11.9.3 Bristol-Myers Squibb Co Sickle Cell Disease Drug Sales, Revenue and Gross Margin (2014-2019)
      • 11.9.4 Bristol-Myers Squibb Co Sickle Cell Disease Drug Products Offered
      • 11.9.5 Bristol-Myers Squibb Co Recent Development
    • 11.10 Calimmune Inc
      • 11.10.1 Calimmune Inc Company Details
      • 11.10.2 Company Business Overview
      • 11.10.3 Calimmune Inc Sickle Cell Disease Drug Sales, Revenue and Gross Margin (2014-2019)
      • 11.10.4 Calimmune Inc Sickle Cell Disease Drug Products Offered
      • 11.10.5 Calimmune Inc Recent Development
    • 11.11 CRISPR Therapeutics
    • 11.12 CSL Ltd
    • 11.13 Daiichi Sankyo Co Ltd
    • 11.14 Editas Medicine Inc
    • 11.15 Errant Gene Therapeutics LLC
    • 11.16 Gamida Cell Ltd
    • 11.17 Genethon SA
    • 11.18 Gilead Sciences Inc
    • 11.19 Global Blood Therapeutics Inc

    12 Future Forecast

    • 12.1 Sickle Cell Disease Drug Market Forecast by Regions
      • 12.1.1 Global Sickle Cell Disease Drug Sales Forecast by Regions 2019-2025
      • 12.1.2 Global Sickle Cell Disease Drug Revenue Forecast by Regions 2019-2025
    • 12.2 Sickle Cell Disease Drug Market Forecast by Product
      • 12.2.1 Global Sickle Cell Disease Drug Sales Forecast by Product 2019-2025
      • 12.2.2 Global Sickle Cell Disease Drug Revenue Forecast by Product 2019-2025
    • 12.3 Sickle Cell Disease Drug Market Forecast by End User
    • 12.4 North America Sickle Cell Disease Drug Forecast
    • 12.5 Europe Sickle Cell Disease Drug Forecast
    • 12.6 Asia Pacific Sickle Cell Disease Drug Forecast
    • 12.7 Central & South America Sickle Cell Disease Drug Forecast
    • 12.8 Middle East and Africa Sickle Cell Disease Drug Forecast

    13 Market Opportunities, Challenges, Risks and Influences Factors Analysis

    • 13.1 Market Opportunities and Drivers
    • 13.2 Market Challenges
    • 13.3 Market Risks/Restraints
    • 13.4 Macroscopic Indicators

    14 Value Chain and Sales Channels Analysis

    • 14.1 Value Chain Analysis
    • 14.2 Sickle Cell Disease Drug Customers
    • 14.3 Sales Channels Analysis
      • 14.3.1 Sales Channels
      • 14.3.2 Distributors

    15 Research Findings and Conclusion

      16 Appendix

      • 16.1 Research Methodology
        • 16.1.1 Methodology/Research Approach
        • 16.1.2 Data Source
      • 16.2 Author Details

      The global Sickle Cell Disease Drug market is valued at million US$ in 2018 and will reach million US$ by the end of 2025, growing at a CAGR of during 2019-2025. The objectives of this study are to define, segment, and project the size of the Sickle Cell Disease Drug market based on company, product type, end user and key regions.

      This report studies the global market size of Sickle Cell Disease Drug in key regions like North America, Europe, Asia Pacific, Central & South America and Middle East & Africa, focuses on the consumption of Sickle Cell Disease Drug in these regions.
      This research report categorizes the global Sickle Cell Disease Drug market by top players/brands, region, type and end user. This report also studies the global Sickle Cell Disease Drug market status, competition landscape, market share, growth rate, future trends, market drivers, opportunities and challenges, sales channels and distributors.

      The following manufacturers are covered in this report, with sales, revenue, market share for each company:
      Acceleron Pharma Inc
      Addmedica SAS
      Angiocrine Bioscience Inc
      Annexin Pharmaceuticals AB
      ArQule Inc
      Bio Products Laboratory Ltd
      Bioverativ Inc
      bluebird bio Inc
      Bristol-Myers Squibb Co
      Calimmune Inc
      CRISPR Therapeutics
      CSL Ltd
      Daiichi Sankyo Co Ltd
      Editas Medicine Inc
      Errant Gene Therapeutics LLC
      Gamida Cell Ltd
      Genethon SA
      Gilead Sciences Inc
      Global Blood Therapeutics Inc

      Market size by Product
      ARQ-092
      BIVV-003
      CAL-H
      CTX-001
      DRX-194
      Others
      Market size by End User
      Hospital
      Clinic
      Others

      Market size by Region
      North America
      United States
      Canada
      Mexico
      Asia-Pacific
      China
      India
      Japan
      South Korea
      Australia
      Indonesia
      Singapore
      Malaysia
      Philippines
      Thailand
      Vietnam
      Europe
      Germany
      France
      UK
      Italy
      Spain
      Russia
      Central & South America
      Brazil
      Rest of Central & South America
      Middle East & Africa
      GCC Countries
      Turkey
      Egypt
      South Africa

      The study objectives of this report are:
      To study and analyze the global Sickle Cell Disease Drug market size (value & volume) by company, key regions, products and end user, breakdown data from 2014 to 2018, and forecast to 2025.
      To understand the structure of Sickle Cell Disease Drug market by identifying its various subsegments.
      To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
      Focuses on the key global Sickle Cell Disease Drug companies, to define, describe and analyze the sales volume, value, market share, market competition landscape and recent development.
      To project the value and sales volume of Sickle Cell Disease Drug submarkets, with respect to key regions.
      To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

      In this study, the years considered to estimate the market size of Sickle Cell Disease Drug are as follows:
      History Year: 2014-2018
      Base Year: 2018
      Estimated Year: 2019
      Forecast Year 2019 to 2025

      This report includes the estimation of market size for value (million US$) and volume (K Pcs). Both top-down and bottom-up approaches have been used to estimate and validate the market size of Sickle Cell Disease Drug market, to estimate the size of various other dependent submarkets in the overall market. Key players in the market have been identified through secondary research, and their market shares have been determined through primary and secondary research. All percentage shares, splits, and breakdowns have been determined using secondary sources and verified primary sources.

      For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.

      Buy now